ImetelChat

More about Bill Walker (tx to 'GernOneShotLeftonGoal'from SA, 18 December 2016) "The linked article states Bill Walker "worked in the Shay-Wright lab back in 2001". Jerry Shay and Woodring Wright have worked together as Ph. D Principle Investigators at the University of Texas Southwestern Medical Ce...

Here is an article (thanks to 'telomerase' from SA) that provides an interesting angle on the current pharma industry and what should be changed in order to bring drugs faster to patients. I copied the whole comment, because otherwise it may disappear behind passwords. Although Trump is mentioned it...

Thanks, bio. I share your observations. Ad 1: the AML trials is even part of the collaboration agreement and was indeed set for the end of 2016. They must have seen some interesting data already by then. Until now, further clinical studies confirm that AML is a valid target. Maybe we will get a surp...

AML: Imetelstat in xenografts derived from AML patients http://www.geron.com/PDFs/Bruedigam-Imetelstat-ASH-2016.pdf (Abstract #578) MF: An analysis of treatment patterns and outcomes of patients with MF http://www.geron.com/PDFs/Mehra-JJ-MF-ASH-2016.pdf (Abstract #4769) ET: Telomere length dynamics...

'Pre-clinical data strongly point to the direction that imetelstat is effecting rapidly proliferating malignant progenitor clones in a multiplicity of myeloid malignancies.'

I suppose the data of the 'numerous pre-clinical studies' that JnJ is sponsoring are supporting this statement.

Indeed. For me Dr.S. sounded upbeat about the chances of imet beating mom and pac. He didn't say that directly, but by emphasizing the poor results of these two Jak-inhibitors he wanted to show that the window of opportunity is wide open for imetelstat.

(New York November 29-30, 2016, from the webcast) Link: http://edge.media-server.com/m/p/ezigwmnm About MF: still the only drug today that has an effect on the malignant progenitor cells which are the sources of these diseases. About MDS: IMerge continues; starting point is the original study with 8...

Sargasso, there will always be competition if be it for the sole reason that no drug works for everybody and for every disease. What I do know is that there is no competing drug that universally attacks the malignant clones in hematologic cancers like imetelstat does (see latest ET study which is ba...

Dr.Scarlett speaking at the Stifel 2016 Healthcare Conference, 15 Nov 2016 at 9:30 am ET By AnonymousWizard, SA 15 Nov 2016, 06.18 ET 'Listened to the Stifel presentation and not much really new but a sort of confirmation and some clarity. The 9.4 Arm enrollment was placed on hold because they felt ...

by Sean Williams, Nov 1, 2016 at 12:23PM Johnson & Johnson's pipeline is flourishing, and these experimental drugs could play a key role. Given the importance of its pharmaceutical operations in driving growth, J&J announced its intent last year to file a new drug application for 10 new molecular e...

Hunt, regarding your 3rd bullet about delaying the milestone payment: I can't hardly believe that delaying this payment outweighs the commercial importance of having imet approved as soon as possible. If imet goes well, they will need to pay this milstone anyway, leaving the only benefit being the i...

Hunt, these are all valid questions. We are left with trying to interpret the scarse information provided by JnJ and Geron. Usually JnJ doesn't speak publicly about new drugs that are in an early testing phase (i.e. P1 and 2). Maybe they will let us know more when imet is in P3. I consider it as a k...

bio, I agree regarding AML and CML. And off course the combos. Dosing: good question, I was wondering about that myself also. I found the following about the dosing (http://www.naturalhealthresearch.org/extrapolation-of-animal-dose-to-human/): Extrapolation of Animal Dose to Human This article shows...

Some highlights from the conference call: 'Janssen has been sponsoring numerous preclinical studies to explore the effects of imetelstat in other hematologic myeloid malignancies.' That's where the CML and AML are coming from. Obviously there is much more going on than we can see. 'University of Cal...

Currently there are 7 abstracs mentioning imetelstat: https://ash.confex.com/ash/2016/webprogram/start.html#srch=words|imetelstat|method|and|pge|1|byDayany|any|bySymposiumany|any In my view the most important are: ET: Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomeras...

So this thread is to collect hypothetical questions for the cc of tomorrow to see afterwards which ones have been addressed and which haven't. My questions would be: - Can you confirm the intention of JnJ to file imetelstat for Frontline MF in 2019? - If yes: when do you expect the Frontline MF tria...

Nice suggestion, Bio. I will start a new topic for that.

see other thread for MDS update.

Btw: Dr.S. always said that trials were to be financed from the milestone payments' cash flow. And if JnJ is a real partner they will ensure that Geron will not be suffocated by lack of cash while the trials are going on. I am sure they will have a mutual understanding on that.

Bio, your figures make a kind of sense as far as I can see. I like those short and simple calculations for getting an idea. Let's see if people like Hoosier or Phill could comment on it. Regarding the pushing to 2020: as you said on SA, it is probably to get more data on durability of CR and PR resp...